Nanobiotix is dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.
Nanobiotix currently develops NanoBiodrugs which are precisely targeting abnormal cells and destroying them through the controlled generation of physical or chemical reactions triggered by external activation. Nanobiodrugs are composed of two parts:
This unique mode of action explains the accuracy of the therapeutic activity and the expected excellent tolerance. Furthermore, because the activity is triggered externally, this implies a total control of the activity of the NanoBioDrugs.
So far Nanobiotix has demonstrated both in vitro and in vivo both the accuracy of the targeting and the tolerance of the NanoBiodrugs currently under development. In vitro experiments have validated the concept of cell destruction through external activation and the absolute control of this process, with the emergence of an activation time-cell destruction function. Promising large animal studies on various cancer models and different compounds are currently under way.
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3
NANOBIOTIX Authorized to Commence NBTXR3 Clinical Trial in Liver Cancers
French ANSM Grants Approval for Nanobiotix’s NBTXR3 Phase II/III Registration Trial for Soft Tissue Sarcoma
NANOBIOTIX Opens First US Office in Boston, Massachusetts
Nanobiotix’s NBTXR3 NanoXray Phase I Clinical Study Results Presented at ASCO
NANOBIOTIX Announces Development Plan for CE Marking of NBTXR3
NANOBIOTIX Selects Second Product for Development, NBTX-IV
ANSM Approves Nanobiotix’s NBTXR3 Clinical Trial for Advanced Cancers
Positive Interim Results from Nanobiotix’s Nanoparticle-Based NBTXR3 Trial for STS
Nanobiotix Announces Collaboration with Key European Nanomedicine Players
PharmaEngine Inks Strategic Deal to Accelerate Nanobiotix’s NBTXR3 Clinical Program
Nanobiotix’ Lead Compound NBTXR3 for Cancer Treatment Receives Approval for First Clinical Trial
Two Major European Players in Nanomedicine Introduces Nanomed TV
Nanobiotix Announces Closing of Series-C Financing to Advance Development of NanoXray
Company Announces Exciting Preclinical Results Using Patented Nanotechnology to Fight Tumors
Ping Wang, Ph.D.
We speak with researchers behind the latest advancement in graphene hBN research that could boost the development of next-generation electronic and quantum devices.
Dr. Laurene Tetard
AZoNano speaks with Dr. Laurene Tetard from the University of Central Florida about her upcoming research into the development of nanotechnology that can detect animal-borne diseases. The hope is that such technology can be used to help rapidly control infected mosquito populations to protect public
Dr. Amir Sheikhi
AZoNano speaks with Dr. Amir Sheikhi from Pennsylvania State University about his research into creating a new group of nanomaterials designed to capture chemotherapy drugs before they impact healthy tissue, amending a fault traditionally associated with conventional nanoparticles.
The Filmetrics F40 turns your benchtop microscope into an instrument for measuring thickness and refractive index.
Nikalyte’s NL-UHV is a state-of-the-art tool that allows the generation and deposition of nanoparticles in an Ultra-High vacuum onto a sample to create a functionalized surface.
The Filmetrics® F54-XY-200 is a thickness measurement tool created for automated sequence measurement. It is available in various wavelength configuration options, allowing compatibility with a range of film thickness measurement applications.